Published in J Thorac Oncol on August 01, 2015
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol (2015) 1.66
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol (2011) 2.88
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer (2012) 2.59
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer (2012) 1.70
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One (2010) 1.69
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. J Biol Chem (2007) 1.44
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity (2003) 1.43
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res (2013) 1.38
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer (2012) 1.31
Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol (2013) 1.23
Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2016) 1.08
Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol (2014) 1.08
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.99
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer (2013) 0.95
Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer (2013) 0.92
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol (2012) 0.92
Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterization. Am J Surg Pathol (2011) 0.91
Programmed Death Ligand-1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2016) 0.91
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res (2014) 0.88
KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas. J Neuropathol Exp Neurol (2015) 0.87
Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book (2013) 0.87
BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol (2015) 0.86
Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases. Brain Pathol (2013) 0.85
A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer. PLoS One (2012) 0.81
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther (2013) 0.81
Anaplastic PXA in adults: case series with clinicopathologic and molecular features. J Neurooncol (2012) 0.80
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thorac Oncol (2013) 0.79
Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res (2014) 0.78
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer (2013) 0.78
Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol (2010) 0.78
Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol (2011) 0.78
The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol (2014) 0.78
Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs (2013) 0.78
Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2016) 0.77
Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases. Clin Neuropathol (2014) 0.77
Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer? Nat Rev Clin Oncol (2013) 0.76
Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2016) 0.76
Prognostic patterns in the histopathology of pulmonary adenocarcinoma. J Clin Oncol (2012) 0.75
A time to test, a time to treat. J Thorac Dis (2012) 0.75
Oncogenic fusions involving exon 19 of ALK. J Thorac Oncol (2012) 0.75
Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2016) 0.75
Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2017) 0.75
Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2017) 0.75
The diagnostic efficacy of combining bronchoscopic tissue biopsy and endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of malignant lesions in the lung. Diagn Cytopathol (2012) 0.75
Genetic testing for metastasis: potential for improved cancer treatment. Future Oncol (2011) 0.75
Giant pulmonary chondroid hamartoma: imaging and pathology correlation of a rare tumor demonstrated with bone scintigraphy and 18F-FDG PET/CT. Clin Nucl Med (2015) 0.75
Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Arch Pathol Lab Med (2016) 0.75